<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002014</url>
  </required_header>
  <id_info>
    <org_study_id>052A</org_study_id>
    <secondary_id>01</secondary_id>
    <nct_id>NCT00002014</nct_id>
  </id_info>
  <brief_title>A Phase I Study to Evaluate the Pharmacokinetics, Safety and Antiviral Effects of Concurrent Administration of Zidovudine (AZT) and 2'3'-Dideoxyinosine (ddI) in Patients With Human Immunodeficiency Virus (HIV)</brief_title>
  <official_title>A Phase I Study to Evaluate the Pharmacokinetics, Safety and Antiviral Effects of Concurrent Administration of Zidovudine (AZT) and 2'3'-Dideoxyinosine (ddI) in Patients With Human Immunodeficiency Virus (HIV)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Glaxo Wellcome</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      To determine the safety and tolerance of various combinations of zidovudine (AZT) and
      didanosine (ddI) administered concurrently. To determine the pharmacokinetics of concurrent
      AZT and ddI administered orally. To evaluate the antiviral, immunologic and virologic effects
      of AZT and ddI administered concurrently.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zidovudine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Didanosine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

        Concurrent Medication:

        Allowed:

          -  Acyclovir not to exceed two 14-day courses of therapy during trial. Discontinue ddI
             while receiving acyclovir.

        Patients must have the following:

          -  Positive HIV antibody using federally licensed ELISA test kit.

          -  CD4 counts &lt; 400 on two consecutive visits within one month prior to entry.

        Prior Medication:

        Allowed:

          -  Zidovudine (AZT) if treated for less than 120 days.

          -  Pharmacologic doses of steroids if given for management of Pneumocystis carinii
             pneumonia (PCP) (not to exceed 21 days).

        Exclusion Criteria

        Co-existing Condition:

        Patients with the following conditions or symptoms are excluded:

        - Visceral or progressive Kaposi's sarcoma (KS) (defined by &gt; 10 new lesions in the thirty
        days prior to entry) or patients who require chemotherapy or radiation therapy for Kaposi's
        sarcoma. Other concurrent neoplasms other than basal cell carcinoma of skin or in situ
        carcinoma of the cervix. Malabsorption as defined by persistent diarrhea ( &gt; 4 stools/day
        for four weeks) which is unresponsive to antidiarrheal agents. Opportunistic infection
        requiring maintenance therapy. History of Central Nervous System opportunistic infections
        (e.g., toxoplasmosis, cryptococcosis). History of seizure disorders. Prior history of
        pancreatitis. History of peripheral neuropathy or any significant signs or symptoms of
        neurological disease. Examinations for peripheral neuropathy should assess changes in
        extremities. Clinically significant hyperuricemia (tophaceous gout, urate nephropathy).
        History of cardiomyopathy.

        Concurrent Medication:

        Excluded:

          -  Intravenous pentamidine.

          -  Intravenous trimethoprim / sulfamethoxazole.

          -  Alcohol.

          -  Suppressive acyclovir therapy (see Inclusion Medications).

          -  Allopurinol.

          -  Probenecid.

          -  Isoniazid (INH).

          -  Dipyridamole.

        Concurrent Treatment:

        Excluded:

          -  Radiation therapy for Kaposi's sarcoma.

        Patients with the following are excluded:

          -  Zidovudine (AZT) intolerance as evidenced by inability to tolerate at least 600 mg AZT
             daily.

          -  Previously intolerant to didanosine (ddI) evidenced by peripheral neuropathy or
             seizures or pancreatitis or gastrointestinal toxicity or hematologic toxicity.

          -  Diseases or conditions listed under Patient Exclusion Co-existing Conditions.

        Prior Medication:

        Excluded:

          -  Zidovudine (AZT) for &gt; 120 days.

          -  Dideoxycytidine (ddC).

          -  Excluded within 30 days of study entry:

          -  Antiretroviral therapy.

          -  Immunomodulators.

          -  Biological response modifiers.

          -  Cytotoxic chemotherapy for Kaposi's sarcoma.

          -  Excluded within 60 days of study entry:

          -  Ribavirin.

        Prior Treatment:

        Excluded within 2 weeks of study entry:

          -  Transfusions.

          -  Excluded within 30 days of study entry:

          -  Radiation therapy for Kaposi's sarcoma.

        Active substance abuse that would impair compliance with study procedures.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>San Francisco AIDS Clinic / San Francisco Gen Hosp</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>941102859</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Miami School of Medicine</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>331361013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New England Med Ctr</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>981224304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 1991</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Didanosine</keyword>
  <keyword>Drug Evaluation</keyword>
  <keyword>Zidovudine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antiviral Agents</mesh_term>
    <mesh_term>Zidovudine</mesh_term>
    <mesh_term>Didanosine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

